Effect of dexmedetomidine on liver postoperative function following living donor hepatectomy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000040629

Enrollment

Unknown

Registered

2020-12-04

Start date

2020-12-01

Completion date

Unknown

Last updated

2022-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic ischemia-reperfusion injury

Interventions

Experimental group:dexmedetomidine

Control group:normal saline

Eligibility

Sex/Gender

All

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 years, ASA I~II; 2. Patients scheduled to undergo laparoscopic living donor hepatectomy with inflow occlusion (Pringle maneuver).

Exclusion criteria

Exclusion criteria: 1. Known allergy or intolerance to trial medication; 2. Converted to open laparotomy; 3. Reduced-size left lateral lobe graft; 4. Patient refusal.

Design outcomes

Primary

Measure	Time frame
Postoperative liver transaminases;The severity of hepatic ischemia reperfusion injury;	—

Secondary

Measure	Time frame
Hemodynamic parameters;Inflammatory cytokine and oxidative stress;Postoperative kidney function;The pathological consequence of liver tissue;Postoperative complications;Other postoperative liver function indicators;Anesthesia medicine dosage;	—

Countries

China

Contacts

Public ContactXue Fushan

Beijing Friendship Hospital, Capital Medical University

xuefushan@aliyun.com+86 10 63138761

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026